This is the final report for the PAHPV-1 project. HPV is the world's most common Sexually transmitted disease (STD). Every year 233 000 affected women die as a result of progressive HPV related disease. Current data suggests that this is due to a lack or diminished immune response against high-risk HPV types. Individuals who lack strong immunity may benefit from vaccination. In the world wide fight against HPV, a number of research centres are now developing (prophylactic) vaccines. In this pilot action, the project ran a clinical trial program in a study population of 200 women to chart the percentage of individuals at risk for progressive HPV 16. Their final report reveals the outcomes of the project, one result was that in women with HPV related diseases HPV 52 was the most common type in the premalignant lesions whereas HPV 16 had the highest prevalence in the carcinoma group.
Download application/zip (35707)
Record Number: 12618 / Last updated on: 2011-04-14